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Chikungunya virus entry is strongly 
inhibited by phospholipase 
A2 isolated from the venom 
of Crotalus durissus terrificus
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Chikungunya virus (CHIKV) is the etiologic agent of Chikungunya fever, a globally spreading mosquito‑
borne disease. There is no approved antiviral or vaccine against CHIKV, highlighting an urgent need 
for novel therapies. In this context, snake venom proteins have demonstrated antiviral activity 
against several viruses, including arboviruses which are relevant to public health. In particular, the 
phospholipase  A2CB  (PLA2CB), a protein isolated from the venom of Crotalus durissus terrificus was 
previously shown to possess anti‑inflammatory, antiparasitic, antibacterial and antiviral activities. 
In this study, we investigated the multiple effects of  PLA2CB on the CHIKV replicative cycle in BHK‑21 
cells using CHIKV‑nanoluc, a marker virus carrying nanoluciferase reporter. The results demonstrated 
that  PLA2CB possess a strong anti‑CHIKV activity with a selectivity index of 128. We identified that 
 PLA2CB treatment protected cells against CHIKV infection, strongly impairing virus entry by reducing 
adsorption and post‑attachment stages. Moreover,  PLA2CB presented a modest yet significant activity 
towards post‑entry stages of CHIKV replicative cycle. Molecular docking calculations indicated that 
 PLA2CB may interact with CHIKV glycoproteins, mainly with E1 through hydrophobic interactions. 
In addition, infrared spectroscopy measurements indicated interactions of  PLA2CB and CHIKV 
glycoproteins, corroborating with data from in silico analyses. Collectively, this data demonstrated 
the multiple antiviral effects of  PLA2CB on the CHIKV replicative cycle, and suggest that  PLA2CB 
interacts with CHIKV glycoproteins and that this interaction blocks binding of CHIKV virions to the 
host cells.
Chikungunya virus (CHIKV), a member of the genus Alphavirus, family Togaviridae1, is the causative agent 
of Chikungunya  fever2. CHIKV virions comprise an icosahedral capsid with a positive single stranded RNA 
genome of approximately 12  kb3 surrounded by a lipid envelope with E1, E2 and E3 glycoproteins in its  surface4,5.
CHIKV was first identified in 1950 in Tanzania, Africa and related to Chikungunya fever in  19556,7. CHIKV is 
transmitted through the bite of Aedes aegypti and Aedes albopictus  mosquito8,9, and, therefore, have been associ-
ated to the epidemics in tropical and subtropical  regions10. Since then, CHIKV outbreaks have been identified 
in many regions including islands of Indian Ocean, India, South-East Asia, France, Italy and the  Americas11. In 
Brazil, the first cases of Chikungunya fever were documented in 2014, and since then, the disease became an 
 endemic12. From January to June of 2020, 48,316 cases and 11 deaths by CHIKV were  notified13.
Chikungunya fever symptoms include fever, nausea, fatigue, arthralgia and  polyarthralgia14. In some rare 
cases, infected individuals can develop hepatitis, myocarditis, and encephalopathy, ultimately leading to death 
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of  patients14,15. Unlike other arboviruses, CHIKV infection can result in chronic symptoms lasting for months 
or years, resulting in a disabling  disease16,17. There are no approved antiviral drugs against CHIKV infection, 
as a consequence the treatment is often palliative and symptomatic, based on analgesics, non-steroidal anti-
inflammatory, rest, and  hydration18.
Given that many approved drugs employed in the treatment of infectious and chronic diseases originated or 
derived from natural  sources19,20, it is reasonable to hypothesize that natural compounds may also be exploited 
to generate antiviral drugs. In this context, proteins isolated from snake venoms represent promising drug 
leads, since they are a complex mixture of lectins, oxidases, disintegrins, metalloproteins, and phospholipases 
A2 (PLA2s)21,22. From these, PLA2s, in its turn, are members of a secreted phospholipases, which can act in the 
cell membranes and play several roles in biological  systems23–25.
The snake venom isolated from Crotalus durissus terrificus has numerous constituents such as crotoxin, 
crotamin, neurotoxin, among  others26,27. Crotoxin is the major constituent of the C. d. terrificus venom. It is 
characterized as a protein complex composed by two noncovalent subunits, the basic subunit phospholipase A2 
 (PLA2CB), and the acid subunit  crotapotin28,29. Subsequently,  PLA2CB is approximately 14 kDa protein which 
possess anti-inflammatory, antiparasitic, and antibacterial  properties30,31.  PLA2CB has also presented activity 
towards viruses such as hepacivirus C (HCV)32, Rocio (ROCV), Mayaro (MAYV), Dengue (DENV) and Yellow 
Fever (YFV)33,34. Russo and coworkers expressed and purified two recombinant  PLA2CB  (rPLA2CB) and partially 
assessed its anti-CHIKV activity. It was found that  rPLA2CB proteins possess lower antiviral activity and higher 
cytotoxicity profile than the native protein, probably due to nine additional amino acid residues present in their 
 sequences35. Considering these previous results, herein we performed thorough in vitro evaluation of the effects 
of the native  PLA2CB on the CHIKV replication cycle.
Results
PLA2CB strongly impairs CHIKV infection in vitro. We investigated the anti-CHIKV activity of the 
 PLA2CB (Fig.  1A) using BHK-21 cells and a recombinant CHIKV that expresses a nanoluciferase reporter 
(CHIKV-nanoluc) (Fig. 1B)36,37. First, the  PLA2CB antiviral activity was evaluated by performing a dose–response 
assay to determine the effective concentration of 50%  (EC50) and cytotoxicity of 50%  (CC50). BHK-21 cells were 
infected with CHIKV-nanoluc and simultaneously treated with  PLA2CB at concentrations ranging from 0.195 to 
200 µg/mL in two-fold serial dilutions, and viral replication was assessed 16 h post-infection (h.p.i.) (Fig. 1C). 
In parallel, cell viability was assessed by an MTT assay.  PLA2CB was found to be able to inhibit virus replication 
to greater than 99%, while the cell viability at the highest concentration tested was 43%. It was determined that 
 PLA2CB has the EC50 of 1.34 µg/mL, CC50 of 172 µg/mL, and the Selectivity Index (SI) of 128 (Fig. 1D). Thus, 
 PLA2CB acts as strongly inhibitor of CHIKV infection with high SI value.
Figure 1.  The activity of Phospholipase  A2CB  (PLA2CB) against CHIKV infection. (A) Phospholipase  A2CB 
protein structure (PDB: 3R0L). (B) Schematic representation of CHIKV-nanoluc genome. (C) Schematic 
description of infectivity assay. (D) BHK-21 cells were treated with concentrations of  PLA2CB ranging from 
0.195 to 200 µg/mL. CHIKV replication was quantified by measuring of nanoluciferase activity (indicated by 
black dot) and cellular viability was measured using an MTT assay (indicated by grey square). The mean values 
of three independent experiments each measured in triplicate including the standard deviation are shown. All 
images were generated using GraphPad Prism 8 and GIMP 2.10.20 (www. gimp. org).
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PLA2CB strongly inhibits early stages of CHIKV infection. Time-of-addition type of experiments 
were used to analyze the effect of  PLA2CB on different stages of CHIKV replication. For all of these assays, cells 
were treated with  PLA2CB at 12.5 µg/mL, a concentration that inhibited virus replication by ~ 91% without affect-
ing cell viability (Fig. 1D).
To assess the protective effects of  PLA2CB against CHIKV infection, cells were pretreated with  PLA2CB for 
1 h at 37 °C, washed extensively with PBS to remove the compound and infected with CHIKV-nanoluc for 1 h. 
Then, the supernatant was removed, cells were added of fresh medium and luciferase levels were measured 
16 h.p.i. (Fig. 2A).  PLA2CB significantly reduced CHIKV-nanoluc infection by 84% (p < 0.01), demonstrating a 
robust protective effect (Fig. 2A). The protective effect did not increase when the compounds was present for all 
duration of the experiment (Fig. 2B), demonstrating that pre-treatment of cells with  PLA2CB inhibited CHIKV 
replication. This data suggests that  PLA2CB acts by protecting cells against infection and/or by affecting early 
stages of CHIKV infection.
To further evaluate the  PLA2CB effect on CHIKV entry to the host cells, virus and  PLA2CB were simultaneously 
added to BHK-21 cells for 1 h at 37 °C, cells were washed with PBS and replaced with fresh medium (Fig. 3A). 
 PLA2CB demonstrated to decrease 95.3% of CHIKV replication (p < 0.0001), indicating that this compound 
strongly inhibited the CHIKV-nanoluc entry (Fig. 3A). Combining this treatment with 1 h pre-incubation of 
the inoculum containing PLA2CB and CHIKV at 37 °C further increased inhibition that reached over 99% 
(Fig. 3B), indicating that  PLA2CB also possesses virucidal activity. To analyze the effect of  PLA2CB on CHIKV 
attachment, virus and compound were first incubated with the cells at 4 °C for 1 h. At this temperature, virus 
particles were able to attach to the cellular receptors, but not entry into the host cells. Cells were then washed 
with PBS, fresh medium added, and incubated at 37 °C (Fig. 3C), to allow the continuation of the entry process. 
Data obtained from this assay also showed strong inhibition of CHIKV attachment by reducing virus entry by 
98.2% to the cells (p < 0.0001) (Fig. 3C). Post-attachment was evaluated by including an additional incubation of 
30 min at 37 °C to the previous protocol (Fig. 3D), showing that the inhibition reminded strong reaching 95.2% 
(p < 0.0001) (Fig. 3D). Taken together this data indicates that  PLA2CB possesses a robust virucidal activity and 
the ability to block virus entry to host cells.
PLA2CB moderately affect post‑entry steps of CHIKV infection. Two assays were used to analyze 
effects of  PLA2CB on post-entry stages of CHIKV infection. Using CHIKV-nanoluc it was found that, if added 
after virus infection, compound cause relatively modest, 64% reduction of CHIKV replication (p < 0.0001) 
Figure 2.  PLA2CB protects cells against CHIKV infection. (A) BHK-21 cells were treated with  PLA2CB 
at 12.5 μg/mL for 1 h. Then, cells were washed and infected with CHIKV-nanoluc at MOI 0.1 for 1 h. The 
compound-containing medium was removed and replaced with a fresh medium. (B) BHK-21 cells were treated 
with the  PLA2CB at 12.5 μg/mL for 1 h, then were infected with CHIKV-nanoluc in the presence of  PLA2CB. 
For both assays, CHIKV replication was measured by nanoluc activity at 16 h.p.i.. Schematic representation of 
each time-based assay as indicated by BHK-21 cells (black bars),  PLA2CB (grey bars), and CHIKV-nanoluc (blue 
bars). Mean values ± SD of a minimum of three independent experiments each measured in triplicate. (****) 
P < 0.0001. All images were generated using GraphPad Prism 8 and GIMP 2.10.20 (www. gimp. org).
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(Fig. 4A). To reveal the effect of  PLA2CB on virus RNA replication in the absence of production and spread of 
virions, BHK-CHIKV-NCT cells were used. This stable cell line contains CHIKV replicon which continuously 
expresses viral nonstructural proteins and two reporters: Renilla luciferase from nonstructural region and EGFP 
via activity of viral subgenomic promoter. Measurement of activities of these reporters allows the evaluation 
of the effect of  PLA2CB on replication complexes formed during the replication stage as well as on production 
and translation of subgenomic RNAs. Treatment of BHK-CHIKV-NCT cells with  PLA2CB at 12.5 µg/mL for 
72 h after treatment revealed the reduction of Renilla luciferase expression by 58% without causing detectable 
cytotoxicity (Fig. 4B); this data confirms observation made using CHIKV-nanoluc. Furthermore, the levels in 
EGFP expression were also reduced as seen in Fig. 4C, indicating decrease of subgenomic RNA synthesis and/
or translation. Taken together, these results suggest that  PLA2CB inhibits post-entry stages of infection possibly 
interfering with functioning of CHIKV nonstructural proteins.
Molecular docking reveals possible interactions between  PLA2CB and CHIKV glycopro‑
teins. Results of inhibition assays clearly demonstrate that  PLA2CB inactivates CHIKV virions and impairs 
their binding to host cell suggesting interaction of compound with outer surface of virion. Therefore, a molecular 
docking assay was performed to investigate interactions and reveal potential binding mode between  PLA2CB and 
CHIKV glycoproteins. In a blind molecular docking,  PLA2CB was predicted to interact with the E1 and E2 of the 
glycoprotein complex, with global energy of − 0.57 kJ/mol after refining (Fig. 5).
The 2D interactions between  PLA2CB and CHIKV glycoproteins showed that  PLA2CB mainly interacts with 
E1 glycoprotein, forming thirty hydrophobic interactions (residues Ile63, Gln33, Pro19, Phe109, Gly31, Ala55, 
Val18, Lys60, Arg114, Phe23, Trp30, Trp61, Leu3 in  PLA2CB and residues Gln353, Lys132, Leu34, Val269, Ser35, 
Asn389, Arg134, Asn140, Tyr390, Leu136, Gln260, Gly12, He344, Glu32, Arg340, Ser355 in E1 glycoprotein) 
(Fig. 6). Also,  PLA2CB formed 3 hydrogens bonds with E1, Ser113 and Asn270 (2.30 Å), Asn58 and Glu343 
(2.95 Å) and His1 and Glu341 (2.18 Å) (Fig. 6).  PLA2CB may also form one hydrogen bond with E2 glycoprotein 
(between Arg11 and Glu 334 (2.07 Å), plus five hydrophobic interactions (Asn105, Lys104, Gly106 in  PLA2CB 
and Asn273, Lys270 in E1) (Fig. 7).
PLA2CB causes molecular changes in CHIKV glycoprotein. To further investigate the interactions 
between  PLA2CB and CHIKV particles, infrared spectroscopy spectral analysis and vibrational analysis among 
the virus and  PLA2CB was performed. Representative means of the infrared spectrum of CHIKV,  PLA2CB, and 
CHIKV plus  PLA2CB, which is the bio fingerprint region representing proteins, lipids, nucleic acids, and glyco-
proteins are shown in Fig. 8A. A representative infrared average spectrum of second derivative analysis from 
CHIKV virions,  PLA2CB, and CHIKV virions plus  PLA2CB is displayed in Fig.  8A. In the second derivative 
Figure 3.  PLA2CB has virucidal activity and blocks CHIKV entry to the host cells. (A) BHK-21 cells were 
infected with CHIKV-nanoluc (MOI 0.1) and simultaneously treated with  PLA2CB at 12.5 μg/mL for 1 h. Cells 
were washed and replaced by fresh medium. (B) CHIKV-nanoluc and  PLA2CB at 12.5 μg/mL were incubated 
for 1 h at 37 °C and then for one extra hour with the cells. Then, virus and compound were removed, cells were 
washed with PBS, and added fresh medium. (C) BHK-21 cells were infected with the virus and simultaneously 
treated with  PLA2CB at 12.5 μg/mL for 1 h at 4 °C. The cells were washed to remove virus and compound and 
replaced with fresh medium. (D) BHK-21 cells were infected with virus and simultaneously treated with  PLA2CB 
at 12.5 μg/mL for 1 h at 4 °C. Then, cells were incubated for additional 30 min with compound and virus at 
37 °C, washed with PBS and replaced by fresh medium. For all assays, CHIKV replication was measured by 
nanoluc activity at 16 h.p.i.. Schematic representation of each time-based assay as indicated by BHK-21 cells 
(black bars),  PLA2CB (grey bars), and CHIKV-nanoluc (blue bars), CHIKV and  PLA2CB inoculum (microtube), 
incubation at 4 °C (ice crystal) and incubation at 37 °C (thermometer). Mean values ± SD of a minimum of 
three independent experiments each measured in triplicate. (****) P < 0.0001. All images were generated using 
GraphPad Prism 8 and GIMP 2.10.20 (www. gimp. org).
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Figure 4.  PLA2CB inhibits post-entry stage of CHIKV. (A) BHK-21 cells were infected with CHIKV-nanoluc 
(MOI 0.1) for 1 h, washed to remove unbound virus and added of medium containing  PLA2CB at 12.5 μg/mL 
for 16 h. Nanoluciferase levels were measured to access CHIKV-nanoluc replication rates. (B) BHK-CHIKV-
NCT cells were seed 24 h prior treatment and treated with  PLA2CB at 12,5 μg/mL for 72 h. Renilla luciferease 
activity and cellular viability measured. (C) Fluorescence of untreated control and  PLA2CB treatment in BHK-
CHIKV-NCT, observed in fluorescence microscopy using 20 × lens (scale bar 400 µm), in GFP filter. Schematic 
representation of each assay as indicated by BHK-21 cells or BHK-CHIKV-NCT (black bars),  PLA2CB (grey 
bars), and CHIKV-nanoluc (blue bars). Mean values ± SD of a minimum of three independent experiments each 
measured in triplicate. (****) P < 0.0001. All images were generated using GraphPad Prism 8 and GIMP 2.10.20 
(www. gimp. org).
Figure 5.  Molecular docking suggests possible interactions between PLA2CB and CHIKV glycoproteins. The 
post-docking 3D image was generated in the DS Visualizer program (Dassault Systèmes BIOVIA, Discovery 
Studio Visualizer, 2016). The CHIKV envelope glycoproteins E1 (Red), E2 (Blue), E3 (green), complexed with 
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analysis, the value heights indicate parallel changes in the intensity of each functional group. The binding inter-
action between CHIKV virions and  PLA2CB was mainly revealed by the increase in the vibrational mode at 
1068  cm−1, which indicates detection of additional stretching of C-O ribose present in glycoprotein derived from 
the association CHIKV virions and  PLA2CB38–40 (Fig. 8B). Furthermore, the Stacked Walls (Fig. 9A) and split 
heat map (Fig. 9B) reinforces the additional expression of vibrational mode at 1068  cm−1 under CHIKV virions 
plus  PLA2CB association.
Discussion
Natural  PLA2CB has shown to have broad spectrum antiviral  activity32–34. Here, we assessed the antiviral activ-
ity of the  PLA2CB against CHIKV, as well as sought comprehension on its mechanism of action. Our results 
demonstrated that  PLA2CB strongly inhibited CHIKV infection, corroborating with Russo and colleagues work, 
which demonstrated that  rPLA2CB impaired CHIKV  infection35. Additionally, the results demonstrated that the 
pre-treatment of naïve cells with  PLA2CB protected host cells against CHIKV infection. In accordance with our 
study, Chen and coworkers have reported that phospholipase A2 isolated from the venom of the honeybee Apis 
mellifera was able to protect cells against Human immunodeficiency virus (HIV) and dengue virus (DENV) 
 infections41. Fenard and colleagues also demonstrated that cells can be protected against HIV infection by differ-
ent phospholipases A2 isolated from several mammalian  species42. The PLA2s from snake venoms are classified 
Figure 6.  Molecular interactions between CHIKV E1 and  PLACB. 2D diagram of the interactions of the 
envelope glycoprotein E1 protein with  PLA2CB. The hydrogen bonds (green dashes) are shown between  PLA2CB 
(purple lines) and E1 glycoprotein (orange lines). Hydrophobic interactions are also shown between  PLA2CB 
(purple bows) and E1 glycoprotein (red bows). All images were generated using GraphPad Prism 8 and GIMP 
2.10.20 (www. gimp. org).
Figure 7.  Molecular interactions between CHIKV E2 and  PLACB. 2D diagram of the interactions of the 
envelope glycoprotein E2 protein with  PLA2CB. The hydrogen bonds (green dashes) are shown between  PLA2CB 
(purple lines) and E1 glycoprotein (orange lines). Hydrophobic interactions are also shown between  PLA2CB 
(purple bows) and E1 glycoprotein (red bows). All images were generated using GraphPad Prism 8 and GIMP 
2.10.20 (www. gimp. org).
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in the group II of a secreted family phospholipases and show homology to the mammalian inflammatory  PLA2, 
which play different roles in the organism including in an immune response to infectious  diseases43–46. Therefore, 
our data might also suggest that  PLA2CB plays a role in host cell metabolism and as a result protects cells against 
viral infection, by the possible mimicking effect of phospholipases found in host cells.
Figure 8.  Infrared spectroscopy Spectral analysis indicates interactions between CHIKV virion and  PLACB. (A) 
Representative infrared average spectrum of second derivative analysis from  PLA2CB (red line), CHIKV virion 
(black line), and  PLA2CB plus CHIKV virion (blue line) employing an Fourrier Transform Infrared (FTIR) 
methodology. (B) Second derivative analysis, which the value heights indicate the intensity of each functional 
group. All images were generated using GraphPad Prism 8 and GIMP 2.10.20 (www. gimp. org).
Figure 9.  Infrared spectroscopy Spectral analysis between CHIKV virion and  PLACB. A representative Stacked 
Walls (A) and split heat map (B) of the infrared average spectrum of second derivative analysis from  PLA2CB 
(red), CHIKV virions (black), and  PLA2CB plus CHIKV virions (blue). All images were generated using 
GraphPad Prism 8 and GIMP 2.10.20 (www. gimp. org).
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Our findings that  PLA2CB has strong virucidal effect and interferes with viral entry to the host cells are con-
sistent with previous findings made for two flaviviruses, DENV and yellow-fever (YFV)34. The authors demon-
strated that incubation of DENV or YFV virions with  PLA2CB results in inhibition of early steps of viral infection 
probably by disrupting virion envelope membrane and/or blocking virus  adsorption33,34. Additionally, Russo 
and coworkers described that incubation of  rPLA2CB with CHIKV prior to the infection of cells significantly 
impaired CHIKV  infectivity35. Therefore, our results are in agreement with previous data that suggested that 
the predominant activity of  PLA2CB is due to its virucidal effect, probably by acting on the virus particle. Several 
PLA2s isolated from snake venom have been described to possess antiviral activity against DENV, YFV, Herpes 
simplex types 1 and 2 and Influenza A (H3N2) by interacting with lipid membrane found in a pocket between 
glycoproteins and/or through attachment to the glycoproteins in the viral envelope  surface33,34,41,47. Based on 
this data, we performed a blind molecular docking using  PLA2CB and the CHIKV glycoproteins complex (E1, 
E2, and E3) to assess the possible interaction among then. The results demonstrated that  PLA2CB most likely 
bonded to both E1 and E2 with E1 being the main target. These results are also consistent with the virucidal effect 
described here and corroborate previously published  data35. The glycoproteins E1 and E2 are essential during 
the early stages of CHIKV infection. The CHIKV glycoprotein E2 is responsible for binding to cells receptors 
such as  MXRA48; the binding occurs in the “canyon” between protomers of CHIKV spike complex. In addition, 
E1 is a viral fusion protein that ensures the envelope fusion with host cells  membranes49,50. Thus, molecules 
that can interact with E1 and/or E2 attachment sites can prevent virus  entry51. We propose that  PLA2CB might 
act be binding to E1 and/or E2 glycoproteins and preventing virion entry by impairing attachment to the cells 
and/or membrane fusion.  PLA2CB/glycoproteins interactions, characterized using an infrared spectrum assay, 
did indeed support the hypothesis of interaction between CHIKV virions and  PLA2CB. On the other hand, it is 
important to emphasize that alphavirus virions exist in two state with different characteristics, a normal infec-
tious state and pre-fusion state when E1 is activated prior to  attachment52–54. In this context, the employment 
of cryogenic electron microscopy (cryo-EM) or atomic force microscopy presents as potential approaches to 
better characterize this interaction.
Moreover,  PLA2CB also demonstrated a modest yet significant ability of inhibit post-entry steps of CHIKV 
infection. Using CHIKV subgenomic replicon it was found that both RNA replication and subgenomic RNA 
synthesis were inhibited. Shimizu and coworkers have previously reported that  PLA2CB also affected the post-
entry steps of HCV  infection32, corroborating with our findings. The mode how  PLA2CB affects RNA replication 
step remains currently unknown. However, it can be speculated that this may be associated with its effect on cell 
membranes that are required for formation of RNA replicase complexes. The exact mechanism of this as well as 
similarities and differences between anti-HCV and anti-CHIKV effects represent topics for additional studies.
In summary, our study evidenced that  PLA2CB isolated from Crotalus durissus terrificus inhibited multiple 
steps of CHIKV infection. The enzyme was able to protect the target cells against CHIKV infection, impaired 
virus entry to the host cells, mainly by virucidal activity, and also disturbed post-entry steps of the CHIKV infec-
tion. Therefore, this data might be useful for further development of new antiviral approaches against CHIKV 
and provide the potential for treatment of Chikungunya fever.
Methods
Compound. The crude venom of Crotalus durissus terrificus was obtained from the “Animal Toxin Extraction 
Center” (CETA), duly registered and approved by the Ministry of the Environment under de process number 
3002678. The venom was collected from 28 specimens from the Morungaba—SP collection under the Brazilian 
Institute for the Environment and Renewing Natural Resources (IBAMA) authorization: 1/35/1998/000846–1, 
and extraction was performed by Jairo Marques do Vale (CETA). All experiments were performed in accordance 
with relevant named guidelines and regulations available in the federal universities, IBAMA and the Ministry 
of Environment. The isolation and purification of phospholipase  PLA2CB (Fig. 1A) from the venom of Crotalus 
durissus terrificus snakes were carried out at the Toxinology Laboratory of the School of Pharmaceutical Sciences 
of Ribeirão Preto, University of São Paulo, as previously  described28,34. The lyophilized protein was dissolved in 
PBS (phosphate buffer saline), filtered, and stored at -80ºC. Dilutions of the stock solution containing the protein 
were made immediately prior to the experiments. For all the performed assays, PBS was used as the untreated 
control. All authors complied with the ARRIVE guidelines.
Cell culture. BHK-21 cells (fibroblasts derived from Syrian golden hamster kidney; ATCC CCL-10), pur-
chased from The Global Bioresource Center (ATCC), were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM, SIGMA-ALDRICH) supplemented with 100U/mL of penicillin (HYCLONE LABORATORIES), 
100 mg/mL of streptomycin (HYCLONE LABORATORIES), 1% dilution of stock of non-essential amino acids 
(Hyclone Laboratories) and 1% of fetal bovine serum (FBS, HYCLONEN LABORATOIRES) in a humidified 
5%  CO2 incubator at 37 °C. Subgenomic replicon (SGR) harboring cell lines (BHK-CHIKV-NCT)37 were main-
tained under the same conditions of BHK-21 cells (ATCC CCL-10), except for the addition of G418 (SIGMA-
ALDRICH) at 5 mg/mL.
Rescue of CHIKV‑nanoluc reporter virus. The CHIKV expressing nanoluciferase reporter (CHIKV-
nanoluc) (Fig. 1B) used for the antiviral assays is based on the CHIKV isolate LR2006OPY1 (East/Central/South 
African genotype). The infectious cDNA of CHIKV-nanoluc was placed under control of the CMV  promoter36. 
To produce CHIKV-nanoluc virions, 2.3 ×  107 BHK-21 cells seeded in a T175  cm2 flask were transfected with 
1.5 μg of CHIKV-CMV-nanoluc plasmid using Lipofectamine 2000 and Opti-Mem medium. 48 h post-transfec-
tion (h.p.t.) the supernatant was collected and stored at − 80 °C. To determine viral titers, 1 ×  105 BHK-21 cells 
were seeded in each of wells of 24 wells plate; 24 h later the cells were infected with tenfold serially dilutions of 
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CHIKV-nanoluc. Cells were incubated with virus for 1 h 37 °C; after this, the inoculums were removed, cells 
were washed with PBS to remove the unbound virus, and fresh medium supplemented with 1% dilution of stock 
of penicillin and streptomycin, 2% FBS and 1% carboxymethyl cellulose (CMC) was added. Infected cells were 
incubated for 2 days in a humidified 5%  CO2 incubator at 37 °C, followed by fixation with 4% formaldehyde 
and staining with 0.5% violet crystal. The viral foci were counted to determine viral titer which was presented in 
plaque forming units per milliliter (PFU/mL).
Cell viability assay. Cell viability was measured by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide] (SIGMA-ALDRICH) assay as previously  described55. BHK-21 cells were plated to 48 well plates 
at a density of 5 ×  104 cells per well and incubated overnight at 37 °C. Medium containing two-fold serial dilu-
tions of  PLA2CB (from 0.195 to 200 µg/mL) was added and cells were incubated for 16 h. After this, the medium 
was replaced with the MTT solution at 1 mg/mL, cells were incubated for 30 min, after which MTT solution 
was and replaced with 300 μL of DMSO (dimethyl sulfoxide) to solubilize the formazan crystals. The absorbance 
was measured at 490 nm on the Glomax microplate reader (PROMEGA). Cell viability was calculated according 
to the equation (T/C) × 100%, where T and C represent the mean optical density of the treated and untreated 
control groups, respectively. The cytotoxic concentration of 50%  (CC50) was calculated using GraphPad Prism 8.
Determination of the effective concentration 50%  (EC50). To assess the antiviral activity of  PLA2CB, 
BHK-21 cells were seeded at a density of 5 ×  104 cells per well into 48 well plates for 24 h and infected with 
CHIKV-nanoluc at a multiplicity of infection (MOI) of 0.1 PFU/cell as described by Oliveira and  coworkers55. 
The  PLA2CB at concentrations ranging 0.195–200 µg/mL was added to growth media. Samples were harvested 
using Renilla-luciferase lysis buffer (PROMEGA) at 16 h post-infection (h.p.i.) and virus replication levels were 
quantified by measuring nanoluciferase activity using the Renilla luciferase Assay System (PROMEGA). The 
effective concentration of 50% inhibition  (EC50) was calculated using GraphPad Prism 8 software. The values of 
 CC50 and  EC50 were used to calculate the selectivity index (SI =  CC50/EC50).
Time‑of‑addition assays. BHK-21 cells at the density of 5 ×  104 cells per well were seeded in 48 well plates 
24 h before infection and treatment. All infections were performed at MOI of 0.1 and efficiency of virus replica-
tion was assessed by measurement of nanoluciferase activity at 16 h.p.i.
In pretreatment assay, cells were treated for 1 h with the compound prior to the CHIKV infection, extensively 
washed with PBS and added of CHIKV-nanoluc for 1 h. Then, cells were washed with PBS and incubated to 
remove unbound virus and added of fresh medium for 16 h (Fig. 2A). Alternatively, cells were treated for 1 h with 
the compound, washed with PBS and infected with CHIKV-nanoluc at the presence (Fig. 2B) of  PLA2CB for 16 h.
In entry inhibition assay, cells were infected using media containing the compound- and virus for 1 h, washed 
with PBS and incubated with fresh medium for 16 h (Fig. 3A). The virucidal activity was assessed using the same 
setting except inoculum containing compound and virus was incubated for 1 h before it was added to the cells 
(Fig. 3B). The impact of compound on attachment step was analyzed using the same setting as in entry inhibition 
assay except cells were incubated with virus and compound at 4 °C (Fig. 3C). A variant of this assay where the 
incubation at 4 °C was followed by incubation for 30 min at 37 °C was used to analyze the effect of compound 
on post-attachment steps of infection (Fig. 3D).
In post-entry assay, cells were infected with CHIKV for 1 h, washed extensively with PBS, and the incubated 
in compound-containing medium for 16 h (Fig. 4A).
RNA replication assay using BHK‑CHIKV‑NCT cells. BHK-CHIKV-NCT cells that express CHIKV 
nonstructural proteins, a selection marker (puromycin acetyltransferase, Pac) and Renilla luciferase and EGFP 
 reporters37, were used to assess the activity of  PLA2CB on CHIKV RNA replication. Cells were seed at a density 
of 7 ×  103 cells per well of a 96 well plate. After 24 h, cells were treated with the  PLA2CB at 12.5 µg/mL for 72 h 
(Fig.  4B). The impact of compound on CHIKV RNA replication was estimated by quantification of Renilla 
luciferase expression. In addition, EGFP fluorescence was monitored by placing plates directly using an EVOS 
(THERMO-FISCHER) fluorescence microscope and using 20 × lens and GFP filter.
Molecular docking analysis. The interaction between  PLA2CB (PDB: 3R0L) and the envelope glycopro-
teins of the CHIKV (PDB: 3N42) was analyzed using blind docking performed in the PatchDock  server56, using 
the parameters predefined by the program and refined by the FireDock  algorithm57. The best docking posi-
tions were evaluated by the geometric complementarity score defined by PatchDock, with results refined and 
ranked by the global energy after refinement. The post-docking 3D image was generated in the DS Visualizer 
program, Dassault Systèmes BIOVIA, Discovery Studio Visualizer, version 17, San Diego: Dassault Systèmes, 
2016, and a 2D diagram of the interactions interface between the molecules was generated with the aid of the 
LigPlot +  program58.
Infrared spectroscopy spectral data analysis. An Fourrier Transform Infrared (FTIR) spectropho-
tometer Vertex 70 (BRUKER OPTICS, REINSTETTEN, Germany) connected to a micro-attenuated total reflec-
tance (ATR) platform was used to record sample signature at 1800  cm−1 to 400  cm−1 regions as described by 
Oliveira and  coworkers55. The ATR unit is composed of a diamond disc as an internal-reflection element. The 
sample dehydrated pellicle penetration depth ranges between 0.1 and 2 μm and depends on the wavelength, 
incidence angle of the beam, and the refractive index of ATR-crystal material. The infrared beam is reflected at 
the interface toward sample in the ATR-crystal. All samples (2µL) were dried using airflow on ATR-crystal for 
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3 min before sample spectra recorded in triplicate. The air spectrum was used as a background in all ATR-FTIR 
analysis. Sample spectra and background were taken with 4  cm−1 of resolution and 32 scans were performed for 
analysis. The spectra were normalized employing the vector method and adjusted to rubber band baseline cor-
rection. The original data were plotted in the Origin Pro 9.0 (ORIGINLAB, Northampton, MA, USA) software 
to create the second derivative analysis. The second derivative was obtained by applying the Savitzky-Golay 
algorithm with polynomial order 5 and 20 points of the window. The value heights indicated the intensity of the 
functional group evaluated.
Statistical analysis. Individual experiments were performed in triplicate and all assays were performed 
a minimum of three times to confirm the reproducibility of the results. GraphPad Prism 8 software was used 
to assess statistical differences of means of readings using Student’s unpaired t-test or Mann–Whitney tests. P 
values < 0.01 were considered to be statistically significant.
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